Member Info for CauldStream7

Monteacute:

Why do you feel sorry for those who bought at 16-17p per share? That price will soon look like a bargain.

Onetomany:

You should call yourself "all too many".

You do go on and on so give us a break. How about limiting your posts to one per week. That should be plenty to allow us an insight into your brilliant ideas. You posted 115 posts in the past month - 100 too many I'd say.

Roger65: continued.

.. ..past 30 days. I presume that your objective is to induce actual or potential investors to withhold their investments in IMM's shares. I have worried about whether I should increase my IMM share holdings because of the repeated assertions by you and your followers like Onetomany that Tim is a lier and have reduced my purchases thereby. I think that has been detrimental to IMM's fortunes - it certainly has been good for your fortunes based on selling high and buying low.

If you have any integrity, you should reduce your postings from 5 per day to 5 per month.

Rogerr65:

In your message on 10 December at 20:07 you wrote "Supermobileman - my posts here have cost shareholders nothing and have no impact on IMM's fortunes. Tim's words do."

Let me tell you that indeed your words do influence the decisions of shareholders in Immupharma - to buy, to sell or to hold. You have invested more time than anyone else in bombarding this bulletin board with your views. I've checked how many times you have messaged the bb - 155 in the past 30 days.

You obviously are lying when you claim that your words do not affect the decisions of shareholders. Ask yourself why on average you sent over 5 messages per day during the past 30 da

Onetomany.

Earlier this morning you wrote that "we would be lucky to get 20p for our IMM shares."

How did you reach this conclusion?

You think that other forecasts which are much higher than yours are rubbish, but at least they are based on NPV calculations like the Professor1's. Your price predictions are based on what? Your last meal?

Hi Rookie1.

Thanks for your positive posts on this bulletin board. You have lots of fortitude in the face of abuse from those contributors who only see the worst in every situation relating to IMM. The latest is from Juxta who is unhappy that IMM's office address is not an entity with lots of office space.

He does not seem to understand that IMM is a small company which has been given the permission by the CNRS, France's leading research institution, to commercialise the discoveries of its research staff.

One of these is the discovery by Professor Sylviane Muller, one of the directors of CNRS, of a peptide with which she planned to cure the autoimmune disease, Lupus. This peptide was called Lupuzor. It failed to pass its Phase 3 trial, largely because of the failure of the drug in the US.

Lupuzor was given a new lease of life with financial support from the American company, Avion, and was advised by the FDA to continue to trial it using much higher doses. At this much higher dosage, Lupuzor was effective and well tolerated by the patients who took part in this new trial.

Professor Muller's work was continued by Dr Sebastien Goudreau IMM's chief scientist, who developed Lupuzor as one of a suite of drugs called P140. He and his principal assistant, Dr Laura Mauran-Ambrosino, have continued research into the P140 drugs suite and have progressed it further so as to show that this family of drugs can not only cure around 50 autoimmune diseases but also diagnose them beforehand.

Nearly 100 years ago, in 1928, Dr Alexander Fleming discovered Penicillin, and in the coming years he and his principal researchers, Howard Florey and Ernst Chain, produced a purified version of it. For their their work, Fleming and his associates were awarded the Nobel Prize in 1945. Their work was worth a fortune, none of which was due to the the cost of their offices and other property. It was all down to their brain power.

Perhaps in the years to come Drs Muller, Goudreau and Mauran-Ambrosino will also receive the Nobel Prize for their work on the P140 drugs. It will have nothing to do with IMM's office and labs. It will be all down to their brain power. Again.

How stupid of otm and others of his ilk to suggest an offer of three times the current sp of IMM as one that would tempt shareholders. A sum of £100m is approx 10p per share. Who apart from an idiot would accept that as other than derisory for a platform of drugs which have the capacity to diagnose and cure up to 50 autoimmune diseases?

If one of the leading pharmas takes this seriously they will pricing the shares in pounds, not pence.

OSD;

Won't it be lovely if all the congregation follow your divinely inspired advice and BUY.

We will then rejoice when the SP rises to 20p by Hogmanay.

Thungelaberg;

I would be appalled if the share price offered to Immupharma was 20p. Even 50p in my view would be disappointing.

Have those who hold these views listened to what Immupharma's Chief Scientific Officer, Dr Goudreau, have said? And he is not alone. For example, Professor Sylvyanne Muller, who discovered the original peptide, Lupuzor, which has formed the basis of the research that has led to the patent for P140.

Immupharma has claimed that P140 is a cure for up to 50 of the most prevalent autoimmune diseases . These drugs can also diagnose these diseases which to date has been difficult to achieve. For these aforesaid reasons, it would not be unremarkable if the Immupharma's share price were at least £4 and perhaps much more.

.

SmTch73.

I guess that you hope to make a further purchase before the SP of IMM starts to soar sky-ward. I've been doing that for a long time, now into 7 figures. The share price is very, very low in my view. At least a ten-bagger.

Morri940:

I think you are being overcautious. The eventual SP for Immupharma agreed in a deal between IMM and a buyer should have nothing to do with the price that would give you a modest profit on your IMM share holding.

I am guided by the opinion of the senior scientists in Immupharma, like Sebastian Goudreau, who believe that the P140 drug platform is an outstanding platform of drugs in having the capacity to cure as many as 50 autoimmune diseases and to be able to diagnose them too. I am also guided by those of us who have the wisdom to analyse the information that is in the public domain, such as Oscar22, and all of whom are agreed that this justifies a valuation of Immupharma that reaches into the billions - ie, around £4 per share.

So around this figure is the share price that I am looking to receive for my IMM shares. And I hope that this is forthcoming in an upfront deal, Ie, probably a buyout.

I am sure that many readers of this Bulletin Board's posts will also know that Scotland, after suffering a wait of 27 years to qualify for the Finals of the Soccer World Cup, did so in great style last night at Hampden Park, Glasgow.

If Scotland managed this feat, I am sure Immupharma can do likewise and pull off a great deal this side of Christmas. Go for it Tim, Tim and Seb!

Morri940.

I'm sorry. I can't understand your message at 1947. Can you please explain it?

Morri940.

I'm sorry. I can't understand your message at 1947. Can you please explain it?

The situation for Immupharma today compared with a year ago has changed dramatically. If you read all the well-researched posts from the like of Oscar22, they explain why Immupharma's future is looking tremendously more profitable than a year ago.

With a patent filed for the P140 stable of drugs with their capability of not only curing around 50 autoimmune diseases, and their capability of diagnosing them as well, it is becoming clear that P140 is revolutionary and over the next 20 years when it is enjoying exclusivity in their commercial development, an agile developer of these drugs is destined to become very wealthy, and so will its shareholders.

So it is pathetic that a few contributors to this board still seem to have as their main mission the denigration of Immupharma and of its CEO. For goodness sake, give the company, its CEO and its tiptop scientists a break and give them your support.

Morri940.

Thanks for your reply.

I think we are in the same boat as far as our share holdings in IMM are concerned.

Morri940:

You say you are one of the firmest supporters of Immupharma but simultaneously say that it is pie in sky to value its shares in pounds rather than in pence.

I don't see how you can hold this position. These two claims are contradictory. If you believe that P140 is able to cure up to 50 autoimmune diseases and not only that, diagnose these diseases using the same drugs from the P140 stable, that is a world apart from claiming a cure for a single disease. Moreover, to claim that these drugs can enable doctors to diagnose these diseases as well as to cure them, that is immense.

How do you value a drug with those curative and diagnostic powers? The problem should revolve around coming up with a price that does justice to P140. That's why it is idiotic to advise us to value P140 at 10p per share. In time to come, it may be that £10 will be seen to be a large undervaluation of this hugely valuable group of drugs.

If you are a true supporter of Immmupharma, think again!

If P140 is as efficacious as is claimed by Tim, why is its price only 10p. If it had the credibility of the antiinfluenza drug for which Merck has paid $9.2 bill, $221.6 per share, surely we should be talking about a price of £10, not 10p, per share for Immupharma.

This is quite a gap. Maybe it's the difficulty that Immupharma faces in bridging this price gap when negotiating with potential buyers that has led to negotiations dragging on without a satisfactory outcome for Immupharma and its shareholders. Isn't it worth hanging tough to add a few billion dollars/pounds more for Immupharma?

Hi Oscar 22 for your brilliant analysis of the business talks between Immupharma and the pharma companies with whom they are negotiating. It sounds very positive and the numbers are very large.

It's such a pity that other posters don't have such a positive approach.

Hi Oscar 22 for your brilliant analysis of the business talks between Immupharma and the pharma companies with whom they are negotiating. It sounds very positive and the numbers are very large.

It's such a pity that other posters don't have such a positive approach.